Preliminary schedule
Pharmaceutical sciences in promoting technological innovation to guarantee healthcare access
11/11 | 12/11 | 13/11 | 14/11 | |
07:30 – 12:00 | Preparing | Registration | ||
Thematic sessions | Thematic sessions | |||
Conference | ||||
Plenary Session | Plenary Session | Plenary Session | ||
12:00-13:30 | Poster Presentation | Poster Presentation | Poster Presentation | |
13:30 – 17:00 | Pre-congress activities | Thematic sessions | Thematic sessions | Thematic sessions |
Plenary Session | Plenary Session | Conference | ||
17:00-18:00 | Talk to the authors | Talk to the authors | Closing ceremony | |
18:00-20:00 | Openning Ceremony Oppening Conference | Posgratuate Programs Forum | ABCF Assembly |
*Preliminary programme
Speakers
Dr. German E. Wassermann
Prof. Wassermann holds a degree in Pharmacy with a habilitation in Food Biochemistry and a Ph.D. in Cellular and Molecular Biology from the Federal University of Rio Grande do Sul. After graduation, he joined the Cristália Laboratory as a Senior Researcher in Protein Purification. He currently serves as Deputy Director of R&D for the Biotechnology Division.
Dr. Sergio Sosa-Estani
Doctor in Medicine from the School of Medicine, University of Buenos Aires, and post-doctoral experience at CEBGH/SPHTM Tulane University (New Orleans, USA). He is Head of the Chagas Clinical Program, Drugs for Neglected Diseases initiative – Institute of Clinical Effectiveness and Health Policy. Professor of the master’s program in Clinical Effectiveness and Health at the University of Buenos Aires. He has performed many epidemiological and clinical research projects on tropical and endemic diseases and re-emerging and emerging diseases. He has researched Chagas disease, HIV/AIDS, Uremic Heamolitic Syndrome, and other infectious diseases.
Prof. Constança Britto
PhD in Biological Sciences – Genetics from the Federal University of Rio de Janeiro (UFRJ). Post-doctorate at the University of Medicine of Montpellier I, France. Senior researcher at the Oswaldo Cruz Foundation. Head of the Molecular Biology and Endemic Diseases Laboratory at the Oswaldo Cruz Institute. She is part of the Coordination of the Chagas Disease Translational Program at Fiocruz. She has experience in Biochemistry (Molecular Biology) and Parasitology, emphasizing Molecular Diagnosis of Neglected Diseases and Technological Development. She has more than 130 articles published in peer-reviewed journals.
Prof. Dalia Dawoud
Associate Research Director at the National Institute for Health and Care Excellence (NICE). She has over 20 years of experience as a health economist and researcher. Her current work is focused on advancing HTA and clinical guideline development methods through research. Prof. Dalia leads the NICE’s newly established HTA Innovation Laboratory (HTA Lab) as well as NICE’s portfolio of European Commission-funded projects, such as IMI NEURONET, IHI PREDICTOR, and AD-RIDDLE, with cumulative funding of over 5 million euros. She is widely published in the area of health economics and outcomes research and serves as Associate Editor of ISPOR journal Value in Health and as Director on ISPOR Board of Directors (2023-2026). Dr. Dalia also holds a position as a professor of clinical pharmacy at the Faculty of Pharmacy, Cairo University, Egypt, and has long-standing experience in the Egyptian healthcare system, both as a pharmacist and academic.
Prof. Gisely Cardoso de Melo
Prof. Gisely is a researcher at the Dr. Heitor Vieira Dourado Tropical Medicine Foundation, an Adjunct Professor at the State University of Amazonas (UFAM), and the Coordinator of the Tropical Medicine Program. She is a recipient of the Research Productivity Fellow CNPq, level E. She has experience in the area of laboratory diagnosis of parasites and molecular biology, working mainly on malaria, resistance to antimalarials, and pharmacogenetics.
Prof. Leticia Veras Costa Lotufo
Full Professor at the Department of Pharmacology at the University of São Paulo. Member of the coordination of the Biota-FAPESP program. She was an affiliate of the Brazilian Academy of Sciences (ABC) and the São Paulo State Sciences Academy (ACIESP). She is an Honorary Professor in the Department of Human Biology at the University of Cape Town (2022-2026) and contributed to training 51 postgraduate students, 70% of whom were women. Her scientific research involves searching for new anticancer drugs based on Brazilian biodiversity, especially in the marine environment, where it has been developing projects to understand microbial biodiversity and its biotechnological potential, aiming at the sustainable development of new drugs.
Prof. Roselena Schuh
Generalist pharmacist and Ph.D. in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul (UFRGS). She is a professor at the Faculty of Pharmacy at UFRGS, a supervisor at PPGCF/UFRGS, and a research professor in the Cells, Tissues, and Genes group at the “Hospital de Clínicas de Porto Alegre”. She researches pharmaceutical nanotechnology and the development of non-viral nucleic acid vectors for gene therapy with the CRISPR / Cas9 system. She works in basic and translational research with in vitro and in vivo applications, especially in nasal, intra-articular, and ocular administration routes.
Prof. Tânia Maria Bellé Bresolin
Prof. Tânia is a Pharmacist with a Ph.D. in Sciences – Biochemistry – from the Federal University of Paraná (UFPR), with a sandwich internship at the “Centre de Recherche sur les Macromolécules Végétales” in Grenoble (France). She was a Professor at the Department of Pharmacy at UFPR (1994-2000) and coordinator from the Postgraduate Program in Pharmaceutical Sciences at the University of Vale do Itajaí (UNIVALI), where she is currently a professor. She has been a Member of the Board of Directors of the Brazilian Association of Pharmaceutical Sciences (ABCF) since 2019, currently holding the position of Treasurer. Prof. Tânia is the current Assessment Coordinator of the Postgraduate Pharmacy area at CAPES (2023-2026).